The Great Health Insurance Unbundling: Why the Next Winners Will Own a Wedge, Not the Whole Stack

The strange thing about health care right now

What if the smartest move in health care is not to build the biggest empire, but to stop depending on other empires?

That sounds counterintuitive in an industry obsessed with scale. For years, the winning story was simple: if you want durability, own more of the stack. Insure the member, manage the pharmacy benefit, steer the specialty drug flow, operate the distribution channel, and keep the data in house. The bigger the integrated machine, the safer the moat.

But the newest moves in the market point to a different reality. Large health organizations are quietly rethinking their dependence on partners that once looked indispensable. At the same time, smaller, more focused players are trying to survive by finding one narrow lane where they can be unmistakably better than the giants.

The real battle is no longer integration versus specialization. It is dependency versus control.

That is the deeper tension connecting these developments. One side is a major insurer reducing reliance on a dominant pharmacy and benefits ecosystem. The other is a nimble insurer trying to win by going deeper into exchanges, rural markets, and condition specific products. Together, they reveal a health care market that is not consolidating into one universal model. It is splintering into strategic wedges.

---

From vertical empires to strategic wedges

For a long time, vertical integration in health care promised certainty. If a company controlled insurance, pharmacy, provider relationships, and specialty distribution, it could theoretically reduce friction and capture margin at every step. In practice, though, integration often creates a different kind of risk: when your system depends too heavily on one external partner, or one internal business line, you inherit their economics, incentives, and instability.

That is why a major payer cutting back reliance on a major pharmacy ecosystem matters more than it may first appear. It is not just a transaction. It is a signal that the old theory of leverage is being revised. The goal is no longer simply to own more. The goal is to own the most strategically important chokepoints and avoid getting trapped inside someone else’s pricing power.

Think of it like a city building its own water supply. The city does not need to own every faucet, pipe, and sink in every building. It only needs control over the reservoir, the treatment system, and the main valves. In health care, those valves are not always the same as the old vertical stack. Sometimes the most valuable control point is pharmacy access. Sometimes it is plan design. Sometimes it is underwriting. Sometimes it is the interface where a consumer chooses a plan in the first place.

That is where the more focused insurer becomes interesting. Instead of trying to dominate all of health care, it is attempting to find a segment where it can be the obvious answer. Exchanges, rural consumers, chronic condition products, and small business coverage are not just product lines. They are wedges into specific populations with specific needs, where precision may beat scale.

This is a subtle but important shift. The future may not belong to the biggest platform. It may belong to the company that can answer a very narrow question with unusual clarity: Who is this for, and why does this product fit their life better than anything else?

---

Why the exchange model is more powerful than it looks

At first glance, health insurance exchanges can seem like a commodity battlefield. Everyone looks similar. Everyone competes on price, network, and benefits. Members compare metal tiers and premiums, then choose the least painful option. That framing makes exchanges seem like a low margin volume game.

But that view misses the strategic opportunity. Exchanges are not just a channel. They are a behavioral sorting mechanism. They concentrate consumers who are already self directing, price sensitive, and often underserved by employer based coverage. In other words, they create a market where a company can win not by being everything to everyone, but by being especially relevant to some people.

That is why geographic expansion and product specialization matter so much. A company that enters more states and tailors offerings around specific conditions is not merely growing linearly. It is learning how to translate a broad platform into a series of micro markets. Each market can be tuned for a different customer pain point, whether that is respiratory disease, rural access, or budget constrained households looking for simplicity.

The insight here is that exchanges reward interpretation, not just distribution. A traditional health insurer often wins by negotiating scale. A more focused player can win by understanding the lived experience of the member.

A person with COPD does not think in terms of abstract network breadth. They think in terms of inhaler access, follow up care, lower administrative headaches, and whether their plan actually helps them avoid a costly flare up. A rural member does not think about theoretical synergy. They think about whether care is reachable, whether digital tools save them a trip, and whether the plan feels designed for a sparse geography rather than an urban assumption.

This is the core mismatch in much of health care: the industry keeps selling portfolios while patients live in stories.

The companies that win will not merely optimize insurance products. They will make the product feel like it was built for a specific life situation.

---

The breakup economy: why dependence is becoming unacceptable

There is another force shaping this moment: the hidden cost of dependence.

In the old model, health care organizations tolerated complex relationships because the alternative was to build expensive capabilities in house. If a large insurer needed pharmacy services, it could outsource and focus on the broader game. But over time, outsourcing at scale can become strategic vulnerability. If the partner grows too powerful, it captures margin, data, or leverage. If the partner is also a competitor, the relationship becomes even more awkward.

That is why reducing reliance on a dominant PBM or pharmacy channel should be read as a strategic de risk, not just a procurement decision. The issue is not merely whether a company can negotiate better terms. It is whether the company can preserve control over the member experience and the economics of care delivery.

This dynamic is not unique to health care. It resembles the way software companies eventually become uncomfortable depending on cloud providers for core infrastructure, or the way retailers become wary of relying on a single marketplace platform for customer acquisition. Once a dependency becomes expensive enough, the organization is forced to ask a harder question: Is this partner a distribution asset, or a tax on our future?

That question is especially acute in health care because the industry has so many intermediaries. Every intermediary may solve one problem while creating another. The more layers between the insurer and the patient, the more likely it is that value leaks out through misaligned incentives, opaque pricing, or fragmented ownership of the relationship.

This is why the emerging pattern feels less like consolidation and more like selective unbundling. Not all integration is disappearing. But the parts of the stack that create the most leverage are being reconsidered one by one. Companies want fewer unnecessary dependencies, even if they cannot own everything.

The result is a new strategic map. The winners will not necessarily be the firms with the largest footprint. They will be the firms with the fewest fragile dependencies in the most important places.

---

A useful framework: the health care wedge test

To understand where value is moving, it helps to use a simple framework: the wedge test.

A wedge is a product, channel, or capability that gives a company disproportionate credibility with a specific group of customers. It works when it satisfies three conditions:

1. Pain is concentrated. The customer has a clear, urgent, and repeatable problem.
2. Incumbents are generic. Larger players serve the market adequately but not specifically.
3. The wedge opens a path to expansion. Once inside, the company can add related products or deepen engagement.

The exchange strategy fits this model. So does condition specific plan design. So does rural targeting. Even a product like a respiratory focused offering can serve as an entry point into broader employer relationships, especially for smaller companies that want to manage chronic condition costs.

This is not the same as the old land and expand model in enterprise software, but the logic is similar. You win initial trust by solving one high friction problem extremely well. Then you use that trust to widen the relationship.

What is new in health care is that the wedge is becoming more important than the platform itself. The platform is still necessary, but no one trusts a generic platform to create differentiation on its own. A broad health plan without a sharp edge may survive. It will not inspire loyalty. It will not command enthusiasm. And in a market where acquisition costs are high and churn is costly, lack of emotional and functional specificity becomes a weakness.

A wedge also changes how you think about profitability. If your strategy is to be all things to all members, you usually need scale before economics improve. But if your strategy is to serve a narrower segment with tight product fit, you can potentially improve medical loss ratios, retention, and cross sell opportunities earlier. That matters because many health businesses do not fail from lack of demand. They fail because the economics of acquiring and serving broad populations are too blunt.

---

The new question: what should a health company actually own?

This is the strategic question hiding underneath all of it. In the old era, a health company wanted to own as much of the value chain as possible. In the new era, the better question is: what must be owned, what can be partnered, and what should be deliberately avoided?

That question is more demanding than it sounds. It requires a company to distinguish between three categories:

• Core control points: capabilities that define economics or member trust, such as pricing logic, care navigation, or specialty access.
• Expandable adjacencies: products that naturally extend the core, such as small business plans following a successful exchange offering.
• Commodity dependencies: functions that are necessary but not differentiating, and may be better sourced externally if they do not create strategic lock in.

This model is useful because too many firms confuse being busy with being strategic. They assume ownership is always better than partnership. But ownership has a cost. It can slow innovation, add operational burden, and distract management from the narrow advantages that actually matter.

The best companies will behave less like empires and more like curators of leverage. They will own the pieces that shape customer trust, economics, and data. They will partner where capability is replaceable. And they will exit relationships that once seemed safe but now look like friction.

That is what makes the current moves so revealing. They suggest a market that is maturing past the fantasy that integration automatically creates resilience. Resilience now comes from clarity: knowing where your edge is, where your dependence is dangerous, and where a focused offering can unlock more value than a sprawling one.

---

Key Takeaways

• Do not confuse size with strategic strength. In health care, the most durable advantage may come from controlling a few crucial decision points, not owning every link in the chain.
• Look for wedges, not just products. The best growth opportunities are often narrow offerings that solve a specific, painful problem for a defined population.
• Treat dependency as a strategic risk metric. If a partner can squeeze your margins, shape your customer experience, or limit your differentiation, the relationship may be costing more than it appears.
• Think in micro markets. Rural consumers, chronic condition patients, and small business buyers are not just segments. They are distinct operating environments that reward tailored design.
• Ask what you must own. Separate core control points from commodity functions, and build around the former instead of trying to dominate everything.

---

The future belongs to the companies that know what not to build

The most important shift in health care may be psychological. For decades, executives were rewarded for expansion, accumulation, and integration. The instinct was to buy adjacent assets, deepen control, and reduce reliance on outsiders. That instinct is still useful, but it is no longer sufficient.

The new advantage is selective discipline. It is the ability to say: we do not need to own the whole stack, but we must own the part that defines the customer relationship. We do not need to serve everyone in the same way, but we must serve some people with exceptional relevance. We do not need a giant empire, but we do need a defensible wedge.

That is the deeper lesson connecting these market moves. Health care is not simply becoming more fragmented. It is becoming more intentional about where value lives. The winners will not be the ones that cling to the broadest footprint. They will be the ones that understand which dependencies to break, which niches to deepen, and which experiences to make indispensable.

In that sense, the future of health care may look less like a fortress and more like a network of sharp edges. And the companies that learn to build one sharp edge at a time may end up stronger than the ones still trying to own the entire map.